Lipocine: Confirmed With FDA Acceptance of Proposal for Nda Filing Enabled by Pivotal Pk Study Comparing Exposure of Lpcn 1154 With IV Infusion of Brexanolone
Lipocine:通过比较Lpcn 1154暴露与静脉注射布雷沙诺龙的关键Pk研究,美国食品药品管理局接受了NDA申请提案,从而证实了Lpcn 1154的暴露情况
Lipocine: Confirmed With FDA Acceptance of Proposal for Nda Filing Enabled by Pivotal Pk Study Comparing Exposure of Lpcn 1154 With IV Infusion of Brexanolone
Lipocine:通过比较Lpcn 1154暴露与静脉注射布雷沙诺龙的关键Pk研究,美国食品药品管理局接受了NDA申请提案,从而证实了Lpcn 1154的暴露情况
使用浏览器的分享功能,分享给你的好友吧